| Entry |
|
|---|
| Name |
Lapatinib ditosylate (USAN);
Lapatinib tosilate hydrate (JAN);
Lapatinib ditosylate monohydrate;
Tykerb (TN);
Tyverb (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C29H26ClFN4O4S. (C7H8O3S)2. H2O
|
|---|
| Exact mass |
942.1841
|
|---|
| Mol weight |
943.4761
|
|---|
| Structure |
|
|---|
| Class |
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG01917 Receptor tyrosine kinase inhibitor
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG01639 CYP2C19 substrate
DG02913 CYP3A4 substrate
DG02925 CYP3A5 substrate
Transporter substrate
DG01665 ABCB1 (P-GP) substrate
DG01913 ABCG2 (BCRP) substrate
|
|---|
| Remark |
| Therapeutic category: | 4291 |
| Product (DG00715): | D04024<JP/US> |
|
|---|
| Efficacy |
Antineoplastic, Receptor tyrosine kinase inhibitor |
|---|
| Disease |
Breast cancer (HER2 overexpressing) [DS: H00031] |
|---|
| Target |
|
|---|
| Network |
| N10009 | Tyrosine kinase inhibitor to HER2 overexpression/amplification |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP3A4 [HSA: 1576], CYP3A5 [HSA: 1577]; CYP2C19 [HSA: 1557], CYP2C8 [HSA: 1558]
Transporter: ABCB1 [HSA: 5243], ABCG2 [HSA: 9429]
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07045 | Antineoplastics - protein kinase inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01E PROTEIN KINASE INHIBITORS
L01EH Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
L01EH01 Lapatinib
D04024 Lapatinib ditosylate (USAN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Lapatinib
D04024 Lapatinib ditosylate (USAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D04024 Lapatinib ditosylate (USAN); Lapatinib tosilate hydrate (JAN)
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
EGFR family
EGFR
D04024 Lapatinib ditosylate (USAN) <JP/US>
ERBB2* (HER2, CD340) [HSA_VAR:2064v1]
D04024 Lapatinib ditosylate (USAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D04024
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D04024
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D04024
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D04024
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D04024
Drug transporters
D04024
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D04024
Polymorphisms and mutations affecting drug response
D04024
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 63
1 O0 O 35.3225 -20.0361
2 C8x C 19.9641 -13.5924
3 N5x N 19.9641 -14.9937
4 C8y C 21.1552 -15.6944
5 C8y C 22.4164 -14.9937
6 C8y C 22.4164 -13.5924
7 N5x N 21.1552 -12.8917
8 C8x C 23.6075 -15.6944
9 C8y C 24.7987 -14.9937
10 C8x C 24.7987 -13.5924
11 C8x C 23.6075 -12.8917
12 N1b N 21.1552 -17.0957
13 C8y C 22.3464 -17.7964
14 C8x C 22.3464 -19.1977
15 C8y C 23.6075 -19.8983
16 C8y C 24.7987 -19.1977
17 C8x C 24.7987 -17.7964
18 C8x C 23.6075 -17.0957
19 X Cl 23.6075 -21.2997
20 O2a O 25.9898 -19.8983
21 C1b C 27.1809 -19.1977
22 C8y C 28.3720 -19.8983
23 C8x C 28.3720 -21.2997
24 C8x C 29.6332 -22.0003
25 C8x C 30.8244 -21.2997
26 C8y C 30.8244 -19.8983
27 C8x C 29.6332 -19.1977
28 X F 32.0155 -19.1977
29 C8y C 25.9898 -15.6944
30 C8x C 26.4102 -17.0256
31 C8x C 27.8115 -17.0256
32 C8y C 28.2319 -15.6944
33 O2x O 27.1109 -14.8536
34 C1b C 29.4455 -14.9937
35 N1b N 30.6591 -15.6944
36 C1b C 31.8727 -14.9937
37 C1b C 33.0862 -15.6944
38 S4a S 34.2999 -14.9937
39 C1a C 35.5134 -15.6944
40 O1d O 35.2907 -14.0029
41 O1d O 33.3089 -14.0029
42 C8x C 38.4645 -17.4460
43 C8x C 38.4645 -18.8473
44 C8y C 39.6780 -19.5480
45 C8x C 40.8917 -18.8473
46 C8x C 40.8917 -17.4460
47 C8y C 39.6780 -16.7454
48 C1a C 39.6780 -20.9491
49 S4a S 39.6780 -15.3442
50 O1d O 39.6780 -13.9429
51 O1d O 41.0794 -15.3442
52 O1d O 38.2767 -15.3442
53 C8x C 38.4645 -17.4460
54 C8x C 38.4645 -18.8473
55 C8y C 39.6780 -19.5480
56 C8x C 40.8917 -18.8473
57 C8x C 40.8917 -17.4460
58 C8y C 39.6780 -16.7454
59 S4a S 39.6780 -15.3442
60 O1d O 39.6780 -13.9429
61 O1d O 41.0794 -15.3442
62 O1d O 38.2767 -15.3442
63 C1a C 39.6780 -20.9491
BOND 66
1 2 3 1
2 3 4 2
3 4 5 1
4 5 6 1
5 6 7 1
6 2 7 2
7 5 8 2
8 8 9 1
9 9 10 2
10 10 11 1
11 6 11 2
12 4 12 1
13 12 13 1
14 13 14 2
15 14 15 1
16 15 16 2
17 16 17 1
18 17 18 2
19 13 18 1
20 15 19 1
21 16 20 1
22 20 21 1
23 21 22 1
24 22 23 2
25 23 24 1
26 24 25 2
27 25 26 1
28 26 27 2
29 22 27 1
30 26 28 1
31 9 29 1
32 30 31 1
33 31 32 2
34 32 33 1
35 33 29 1
36 30 29 2
37 32 34 1
38 34 35 1
39 35 36 1
40 36 37 1
41 37 38 1
42 38 39 1
43 38 40 2
44 38 41 2
45 42 43 2
46 43 44 1
47 44 45 2
48 45 46 1
49 46 47 2
50 42 47 1
51 44 48 1
52 47 49 1
53 49 50 1
54 49 51 2
55 49 52 2
56 53 54 2
57 54 55 1
58 55 56 2
59 56 57 1
60 57 58 2
61 53 58 1
62 55 63 1
63 58 59 1
64 59 60 1
65 59 61 2
66 59 62 2
BRACKET 1 37.6600 -21.8400 37.6600 -13.1600
1 41.9300 -13.1600 41.9300 -21.8400
1 2
ORIGINAL 1 42 43 44 45 46 47 49 50 51 52 48
REPEAT 1 53 54 55 56 57 58 59 60 61 62 63
|
|---|
